NSAIDs and COX-2 inhibitors: What can we learn from large outcomes trials? The gastroenterelogist's perspective

Clinical and Experimental Rheumatology

Volumn 19, Issue 6 SUPPL. 25, 2001, Pages

  Hawkey, C J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Clinical trial; COX 2 inhibitors; NSAIDs; Outcomes; Prostaglandins; Ulcers

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; MISOPROSTOL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; SULINDAC;

ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM EXAMINATION; DRUG SAFETY; DRUG USE; ENZYME INHIBITION; ERADICATION THERAPY; GASTROENTEROLOGY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEART INFARCTION; HELICOBACTER PYLORI; HUMAN; LEARNING; METHODOLOGY; OUTCOMES RESEARCH; PREDICTION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; ULCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CORONARY THROMBOSIS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; GASTROENTEROLOGY; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MISOPROSTOL; MYOCARDIAL INFARCTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS; STOMACH; STOMACH ULCER;

EID: 0034777799     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial
2. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
4. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients
5. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: Results of the safety and efficacy large-scale evaluation of in osteoarthritis
6. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen
7. Management of nonsteroidal anti-inflammatory drug-related peptic ulcer bleeding
8. Outcomes studies of drug induced ulcer complications: Do we need them and how should they be done?
9. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
10. Rofecoxib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production
11. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen
12. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin
13. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects
14. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
15. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
16. Stratifying the risk of clinical upper GI events in NSAID users: Results from a double-blind outcomes study (Abstract)
17. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of platelet effects
18. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
19. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison
20. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
21. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids
22. Meloxicam
23. Gastrointestinal tolerability of meloxicam and piroxicam: A double-blind placebo-controlled study
24. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH
25. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs
26. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomised controlled trials
27. Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial
28. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs
29. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: A meta-analysis of randomized controlled clinical trials
30. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study
31. Ranitidine: Differential effects on gastric bleeding and mucosal damage induced by aspirin
32. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
33. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs
34. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed
35. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs
36. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
37. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor